三阴乳腺癌患者临床病理特征及免疫组织化学指标临床意义分析
|
摘要
目的分析三阴乳腺癌患者临床病理特征及免疫组织化学指标意义,为临床上对三阴乳腺癌患者的治疗提供参考依据。方法选取三阴乳腺癌患者共110例,为研究组,选取同时期收治的非三阴乳腺癌患者共110例,为对照组,对比分析两组患者临床病理特征及预后情况,采用免疫组织化学法,检测两组患者P-gp、ERβ、Ki-67等免疫组织化学指标并进行比较。结果研究组患病年龄、组织学分级、肿瘤直径大小、分化程度、淋巴结状态、病理类型与对照组比较,差异有统计学意义(P <0. 05);研究组的月经状态相对于对照组,差异无统计学意义(P> 0. 05);研究组总体生存率、无复发生存率均低于对照组,差异有统计学意义(P <0. 05); ERβ、Ki-67阳性表达率研究组与对照组对比,差异有统计学意义(P <0. 05); P-gp阳性表达率研究组与对照组对比,差异无统计学意义(P> 0. 05); ERβ阳性表达与患病年龄、组织学分级、肿瘤直径大小存在显著相关性; P-gp、Ki-67阳性表达与组织学分级存在显著差异,差异有统计学意义。结论ERβ、P-gp、Ki-67等免疫组织化学指标可作为预测三阴乳腺癌预后情况的参考指标,对于该病的治疗有重要意义。
Objective To analyze the clinicopathological features and immunohistochemical significance of triple-negative breast cancer,and to provide reference for the treatment of patients with triple-negative breast cancer. Methods 110 patients with triple-negative breast cancer were selected as the study group. 110 patients with non-triple-negative breast cancer were selected as the control group. Comparative analysis of clinical pathological features and prognosis of the 2 groups of patients were conclucted. Immunohistochemistry was used to detect and compare the immunohistochemical markers of P-gp,ERβ,and Ki-67 in the2 groups of patients. Results The age,histological grade,tumor diameter,differentiation degree,lymph node status and pathological type of the 2 groups,the difference was statistically significant( P < 0. 05). The menstrual status of the study group was significantly higher than that of the control group( P < 0. 05). The overall survival rate and relapse-free survival rate in the study group were lower than those of the control group,and the difference was statistically significant( P < 0. 05). The positive expression rate of ERβ and Ki-67 in the study group was significantly higher than that in the control group( P < 0. 05). The positive expression rate of P-gp in the study group was not significantly different from that of the control group( P > 0. 05). The positive expression of ERβ was significantly associated with the age of disease,histological grade,and tumor size. There was significant difference between P-gp and Ki-67 positive expression and histological grade,the difference was statistically significant. Conclusion ERβ,Pgp,Ki-67 and other immunohistochemical indicators can be used as a prognostic indicator of the prognosis of triple negative breast cancer,it is important for treatment.
Objective To analyze the clinicopathological features and immunohistochemical significance of triple-negative breast cancer,and to provide reference for the treatment of patients with triple-negative breast cancer. Methods 110 patients with triple-negative breast cancer were selected as the study group. 110 patients with non-triple-negative breast cancer were selected as the control group. Comparative analysis of clinical pathological features and prognosis of the 2 groups of patients were conclucted. Immunohistochemistry was used to detect and compare the immunohistochemical markers of P-gp,ERβ,and Ki-67 in the2 groups of patients. Results The age,histological grade,tumor diameter,differentiation degree,lymph node status and pathological type of the 2 groups,the difference was statistically significant( P < 0. 05). The menstrual status of the study group was significantly higher than that of the control group( P < 0. 05). The overall survival rate and relapse-free survival rate in the study group were lower than those of the control group,and the difference was statistically significant( P < 0. 05). The positive expression rate of ERβ and Ki-67 in the study group was significantly higher than that in the control group( P < 0. 05). The positive expression rate of P-gp in the study group was not significantly different from that of the control group( P > 0. 05). The positive expression of ERβ was significantly associated with the age of disease,histological grade,and tumor size. There was significant difference between P-gp and Ki-67 positive expression and histological grade,the difference was statistically significant. Conclusion ERβ,Pgp,Ki-67 and other immunohistochemical indicators can be used as a prognostic indicator of the prognosis of triple negative breast cancer,it is important for treatment.
引文
[1]王丽娜,张崇建,李连方,等.三阴性乳腺癌表柔比星和环磷酰胺联合紫杉醇周疗新辅助化疗临床观察[J].中华肿瘤防治杂志,2015,22(3):211-215.
[2]Millis SZ,Gatalica Z,Winkler J,et al.Predictive Biomarker Profiling of>6000 Breast Cancer Patients Shows Heterogeneity in TNBC,With Treatment Implications[J].Breast Cancer Res,2015,15(6):473-473.
[3]朱明华,阳泽龙,胡朔枫,等.三阴性乳腺癌临床病理特征及其与预后的关系[J].空军医学杂志,2015,45(2):89-91.
[4]陈崇,周桃玉,温旺荣.家族性和三阴性乳腺癌血清中miR-21的表达[J].暨南大学学报(自然科学与医学版),2015,36(1):50-55.
[5]管小青,郑向欣,顾书成,等.三阴性乳腺癌组织中Ki67、p53的表达及临床意义[J].现代肿瘤医学,2015,23(6):786-791.
[6]杜娟,阮祥燕.三阴乳腺癌的特点及研究进展[J].首都医科大学学报,2015,36(4):578-582.
[7]张明,高嫦娥,邹天宁,等.不同新辅助化疗方案对三阴性乳腺癌治疗疗效临床分析[J].昆明医科大学学报,2015,36(1):65-68.
[8]Shin M,Lee KE,Yang EG,et al.PEA-15 facilitates EGFRdephosphorylation via ERK sequestration at increased ER-PM contacts in TNBC cells[J].Febs Letters,2015,589(9):1033-1033.
[9]Schmidt G,Gerlinger C,Juhaszb9ss I,et al.Her2-neu score as a prognostic factor for outcome in patients with triplenegative breast cancer[J].Breast Cancer Res,2016,142(6):1369-1376.
[10]李雯,冯彦林.SUV_(max)、Ki-67、p53、EGFR对三阴性乳腺癌新辅助化疗疗效的预测价值[J].肿瘤防治研究,2016,43(1):45-47.
[11]朱信信,杨红鹰.三阴性乳腺癌相关分子标记物的表达及临床特征分析[J].诊断病理学杂志,2015,22(1):53-56.
[12]翁剑华,许素真,胡美笑.ki67在三阴性乳腺癌中的表达及意义[J].临床和实验医学杂志,2016,15(2):126-128.
[13]Fontanella C,Lederer B,Gade S,et al.Impact of body mass index on neoadjuvant treatment outcome:a pooled analysis of eight prospective neoadjuvant breast cancer trials[J].Breast Cancer Res,2015,150(1):127-39.
[14]Hall C,Karhade M,Laubacher B,et al.Circulating Tumor Cells After Neoadjuvant Chemotherapy in Stage I-III TripleNegative Breast Cancer[J].J Am Coll Surg,2015,22(3):552-558.
[2]Millis SZ,Gatalica Z,Winkler J,et al.Predictive Biomarker Profiling of>6000 Breast Cancer Patients Shows Heterogeneity in TNBC,With Treatment Implications[J].Breast Cancer Res,2015,15(6):473-473.
[3]朱明华,阳泽龙,胡朔枫,等.三阴性乳腺癌临床病理特征及其与预后的关系[J].空军医学杂志,2015,45(2):89-91.
[4]陈崇,周桃玉,温旺荣.家族性和三阴性乳腺癌血清中miR-21的表达[J].暨南大学学报(自然科学与医学版),2015,36(1):50-55.
[5]管小青,郑向欣,顾书成,等.三阴性乳腺癌组织中Ki67、p53的表达及临床意义[J].现代肿瘤医学,2015,23(6):786-791.
[6]杜娟,阮祥燕.三阴乳腺癌的特点及研究进展[J].首都医科大学学报,2015,36(4):578-582.
[7]张明,高嫦娥,邹天宁,等.不同新辅助化疗方案对三阴性乳腺癌治疗疗效临床分析[J].昆明医科大学学报,2015,36(1):65-68.
[8]Shin M,Lee KE,Yang EG,et al.PEA-15 facilitates EGFRdephosphorylation via ERK sequestration at increased ER-PM contacts in TNBC cells[J].Febs Letters,2015,589(9):1033-1033.
[9]Schmidt G,Gerlinger C,Juhaszb9ss I,et al.Her2-neu score as a prognostic factor for outcome in patients with triplenegative breast cancer[J].Breast Cancer Res,2016,142(6):1369-1376.
[10]李雯,冯彦林.SUV_(max)、Ki-67、p53、EGFR对三阴性乳腺癌新辅助化疗疗效的预测价值[J].肿瘤防治研究,2016,43(1):45-47.
[11]朱信信,杨红鹰.三阴性乳腺癌相关分子标记物的表达及临床特征分析[J].诊断病理学杂志,2015,22(1):53-56.
[12]翁剑华,许素真,胡美笑.ki67在三阴性乳腺癌中的表达及意义[J].临床和实验医学杂志,2016,15(2):126-128.
[13]Fontanella C,Lederer B,Gade S,et al.Impact of body mass index on neoadjuvant treatment outcome:a pooled analysis of eight prospective neoadjuvant breast cancer trials[J].Breast Cancer Res,2015,150(1):127-39.
[14]Hall C,Karhade M,Laubacher B,et al.Circulating Tumor Cells After Neoadjuvant Chemotherapy in Stage I-III TripleNegative Breast Cancer[J].J Am Coll Surg,2015,22(3):552-558.